Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients Faggioni M; Hwang HS; van der Werf C; Nederend I; Kannankeril PJ; Wilde AA; Knollmann BCCirc Res 2013[Feb]; 112 (4): 689-97RATIONALE: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) genes. Sinoatrial node dysfunction associated with CPVT may increase the risk for ventricular arrhythmia (VA). OBJECTIVE: To test the hypothesis that CPVT is suppressed by supraventricular overdrive stimulation. METHODS AND RESULTS: Using CPVT mouse models (Casq2(-/-) and RyR2(R4496C/+) mice), the effect of increasing sinus heart rate was tested by pretreatment with atropine and by atrial overdrive pacing. Increasing intrinsic sinus rate with atropine before catecholamine challenge suppressed ventricular tachycardia in 86% of Casq2(-/-) mice (6/7) and significantly reduced the VA score (atropine: 0.6+/-0.2 versus vehicle: 1.7+/-0.3; P<0.05). Atrial overdrive pacing completely prevented VA in 16 of 19 (84%) Casq2(-/-) and in 7 of 8 (88%) RyR2(R4496C/+) mice and significantly reduced ventricular premature beats in both CPVT models (P<0.05). Rapid pacing also prevented spontaneous calcium waves and triggered beats in isolated CPVT myocytes. In humans, heart rate dependence of CPVT was evaluated by screening a CPVT patient registry for antiarrhythmic drug-naive individuals that reached >85% of their maximum-predicted heart rate during exercise testing. All 18 CPVT patients who fulfilled the inclusion criteria exhibited VA before reaching 87% of maximum heart rate. In 6 CPVT patients (33%), VA were paradoxically suppressed as sinus heart rates increased further with continued exercise. CONCLUSIONS: Accelerated supraventricular rates suppress VAs in 2 CPVT mouse models and in a subset of CPVT patients. Hypothetically, atrial overdrive pacing may be a therapy for preventing exercise-induced ventricular tachycardia in treatment-refractory CPVT patients.|*Heart Rate/drug effects[MESH]|Adult[MESH]|Animals[MESH]|Atropine/pharmacology/therapeutic use[MESH]|Bradycardia/genetics/physiopathology[MESH]|Caffeine/toxicity[MESH]|Calcium Signaling/physiology[MESH]|Calsequestrin/deficiency/genetics/physiology[MESH]|Cardiac Pacing, Artificial[MESH]|Exercise Test[MESH]|Humans[MESH]|Isoproterenol/toxicity[MESH]|Mice[MESH]|Mice, Inbred C57BL[MESH]|Mice, Knockout[MESH]|Middle Aged[MESH]|Myocytes, Cardiac/drug effects/physiology[MESH]|Polymorphic Catecholaminergic Ventricular Tachycardia[MESH]|Random Allocation[MESH]|Ryanodine Receptor Calcium Release Channel/deficiency/genetics/physiology[MESH]|Sinoatrial Node/physiopathology[MESH]|Sympathectomy, Chemical[MESH]|Tachycardia, Ventricular[MESH]|Vagus Nerve/drug effects/physiopathology[MESH]|Ventricular Premature Complexes/etiology/prevention & control[MESH] |
